Syndax Pharmaceuticals discusses plans to expand its pipeline and advance lead therapies in an investor presentation and accompanying transcript. The materials focus on the company’s next phase of development, highlighting updates to clinical and research efforts connected to its current pipeline. Across the coverage, Syndax emphasizes building on existing programs by moving forward with development activities and refining its approach to innovation for lead candidates. The discussion centers on how the pipeline is expected to evolve, including the timing and strategic intent behind advancing therapies through subsequent stages of development.

Because the provided excerpts only reference the existence of the slideshow and transcript without including specific results or dates, the reports do not disclose detailed trial outcomes, endpoints, or quantified milestones in the supplied text. However, the overall thrust across the sources is consistent: Syndax is communicating a forward-looking development roadmap, describing how it plans to broaden its pipeline and progress its lead therapeutic programs.